MR461 - A long term follow-up study of Aperts Syndrome
University of Oxford · Academic
In term In term in the September 2026 edition: the latest version runs to 28 September 2026.
- Reference
- DARS-NIC-148106-PP9LS
- Current version
- v4.4
- Term of current version
- 29 September 2025 to 28 September 2026
- Start date
- Before 1 August 2019
- Data controller
- Sole Data Controller
- Commercial purposes
- No
- Sublicensing
- No
- Files released to date
- 0
Why the data was released
Objective for processing
The Data will be used for the purpose of a research project: a long-term follow-up study of individuals with Apert Syndrome.
Data were collected for this study from 1994 to 2013, from which time no further data have been collected. The original data processing finished in 2015, when information on ages at event (death, cause of death, still living on 08/05/2013), with all identifiers removed, were provided to a statistical epidemiologist substantively employed by the University of Oxford. The findings (now in aggregated form) have been ready for publication since 2015 but this was delayed pending clarification of the legal basis for retaining the data.
Over the 10 years that have elapsed since the original data processing in 2015, statistical methodologies have improved. On fresh review of the 2015 manuscript, it has become evident that estimates for standardised mortality ratios could now be substantially improved using better statistical methods. The type of results reported would not change, but improved estimates may be of correspondingly greater value – scientifically, clinically, and for patients with Apert syndrome – in improving our understanding of how the condition affects mortality.
After the additional data processing, the manuscript would be modified to include the improved estimates of confidence limits of the standardised mortality ratios. This Agreement permits the release of the manuscript for publication, and the processing of the data for the purpose of secure storage and back up to ensure it is possible to verify the conclusions published from this study.
Following publication of the study findings, it is possible that the findings will be questioned or challenged by third parties through direct contact with the University of Oxford, contact via the publishing journal or an open letter. In such circumstances, the University of Oxford may re-run the previous analyses undertaken to verify that the published results are accurate and may write a response to be issued directly to the challenger, and/or published.
Since 1960 there has been very little further research into Apert syndrome in this country until in 1994 a new study was created at the University of Oxford. The purpose of this new study at the University of Oxford was to try to find out what causes Apert syndrome. Apert syndrome is a rare malformation syndrome comprising two distinctive features, namely a characteristic appearance of the face and skull due to early closure of the skull bones (craniosynostosis) and bony fusions of the fingers and toes (syndactyly). This due to an alteration in one of the many thousands of genetic instructions which human beings carry from the time of conception. This study has already managed to identify which particular genetic instruction is altered, but much work needs to be done to try to understand why the alteration occurs in the first place, and how it causes the features of Apert syndrome.
In 1994 the University of Oxford sought permission from the head researcher of the 1959 study (who was based at the University of Sheffield) in order to obtain the names and dates of birth of the 24 participants in the 1959 study. These are the only data subjects.
The University of Oxford used these details to obtain data from the Medical Research service under the Office of Population Censuses and Surveys (OPCS). in January 1995. The service subsequently transferred to the Office for National Statistics (ONS) and then the Health and Social Care Information Centre. This detail was used to give the University of Oxford two options;
1 - Should the participant have passed away at time of flagging, the University of Oxford obtained the cause of death, and cancer registration data to understand whether there was an increased incidence of certain cancers.
2 - Should the participant be alive at time of flagging, the University of Oxford would invite them through their General Practitioner to take part in the study.
This study is considered to be in the public interest because it provides new (not previously available) information on the long-term survival of the medical disorder Apert syndrome. The retention of the data, which is now pseudonymised, is not expected to raise ethical issues because no individually identifying information on ages and causes of death is held.
This (currently unpublished) study provides very valuable information for people with Apert syndrome and their parents and carers, because it establishes for the first time that many individuals with the condition live into their 50s-70s. Moreover, although mortality is higher than average before this age, the causes are varied with no one frequent cause (for example a particular type of cancer), being revealed by the data. There is a strong public interest in making these findings widely known by publication in the medical literature.
Data collected were mortality, demographics and cancer data from 1994 until 2013. Since then, actions have been taken to pseudonymise the Apert Syndrome data. These included converting date of birth to week and month of birth, deleting names, and deleting NHS Numbers. No identifying details are held by the University of Oxford in respect of this study.
The analysis of the data completed in 2015, when information on ages at event (death, cause of death, still living on 8/5/2013), with all identifiers removed, were provided to a University of Oxford statistician who has completed a paper on this Apert syndrome. No external parties have previously been involved in this work.
Processing activities
Data collection for this study is now completed.
Additional processing of the data is proposed because estimates for standardised mortality ratios could now be substantially improved using better statistical methods, compared to those available in 2015. Specifically, the previous analysis did not make use of detailed information on population-level mortality rates by calendar year. There have been large changes in mortality rates during the time since the 1959 study on which the data is based. We have assessed that failing to account for these changes could add substantial additional error to the estimates. In this amendment, we therefore propose to use annual, age-specific mortality rates, available from public sources, to calculate more accurate estimates of standardised mortality rates for this cohort of patients with Apert syndrome.
All data analysis by the statistical epidemiologist would take place physically based in the office of the Principal Investigator, located at MRC-Weatherall Institute of Molecular Medicine, University of Oxford (MRC-WIMM). The data are housed on an encrypted memory stick which would be accessed using a laptop computer in the MRC-WIMM. A backup data file will be kept on a second encrypted memory stick with identical security specifications. The statistical epidemiologist would access summary mortality datasets online and use these to estimate mortality rates for the general population at the same ages and chronological times as observed for the individuals with Apert syndrome in this study. These mortality rates will be used to compute the total expected number of deaths for the individuals in the study if they had no difference in mortality from the general population. Standardised mortality rates will then be computed by dividing the observed number of deaths in the study by the expected number.
This Agreement does not permit any onward sharing of the data. The data may be viewed for the purpose of an audit.
If any further data processing is required in addition to the above purposes or if the data needs to be moved to a different location/organisation the applicant must submit an amendment request to NHS Digital and enter into an Amended Data Sharing Agreement before the data is accessed.
In the event that the data needed to be accessed for the purposes of audit or to enable verification of previous findings, the dataset with authorisation from the Principal Investigator will be accessed by the study statistician only for the purposes of verifying results of previous analyses by rerunning analyses that were previously undertaken. Data would be accessible only for as long as is required to enable verification of the analyses and to write a response as appropriate.
The Data may not be transferred to any other location and may only be accessed by substantive employees of the University of Oxford or named Honorary Contract holders for the purposes described above.
Study data needs to be retained and accessible for 2 years after publication.
Expected output
Further processing of the data will be undertaken by the statistical epidemiologist as described in the previous section, to enable improved estimates of standardised mortality rates for this cohort of patients with Apert syndrome. These estimates will be incorporated into the revised manuscript prepared in 2015, which will be submitted for publication. No other analyses will be undertaken using the data under this Agreement.
An online article would be prepared for Headlines, the UK Craniofacial Support Group, so that parents of children with Apert syndrome, and affected young adults, would be made aware of the findings. No new use of the data would be required for this. It would simply be targeting the already-existing information to a specific audience and in simple language.
A summary of the findings would be published in a peer-reviewed medical genetics journal, for example, American
Journal of Medical Genetics.
Causes of death, or whether still alive at the end of the study, would be summarised in 5-year bins. As there are only 24 data subjects in the study, each 5-year bin contains fewer than 5 individuals and consequently if someone knew of a person who had Apert syndrome and was in the 1959 study and died within a specific 5-year age-range, they may be able to identify that person. However, the only additional information they may be able to determine about this individual from the summary data might be their primary cause of death which is a matter of public record. Death and cancer data would be summarised in the form of Kaplan-Meier survival curves or similar demonstrating the proportion of individuals still alive at a given age.
An Open Access charge would be paid to the publisher of the peer-reviewed article, to ensure that the article could be read by anybody wishing to do so.
The Headlines web-based article would ensure that the knowledge reached the relevant patient/parent group.
The Publication is expected to be made available for submission of manuscript for peer-review towards the end of
2025, with publication and associated Headlines article in 2026.
This is the sole planned data dissemination and therefore integral to the overall purpose of the work.
Expected measurable benefits
It is expected that this will improve knowledge of long-term prognosis of Apert syndrome, and causes of mortality, in adulthood. This will assist health professionals in providing better quality, evidence-based information to patients with Apert syndrome and their parents. Improved medical knowledge about this rare condition represents a public good.
The peer-reviewed publication will provide the objective data supporting the broad conclusions. The Headlines article will make these data known to the patient/parent constituent groups.
The benefits anticipated are two-fold:
(i) Psychological: Apert syndrome is a serious disorder providing many challenges for affected children and their parents. It will be very reassuring for families to know that being affected by Apert syndrome does not in addition indicate a high likelihood of early mortality as an adult because of a particular later-onset disease.
(ii) Scientific. It is known that one of the most common genetic associations of endometrial cancer is the identical FGFR2 mutation to that causing Apert syndrome, but occurring as a somatic mutation (i.e. in a particular cell in the body at a later stage of life, rather than something you are born with). It is of great scientific interest that being born with the identical mutation is not necessarily associated with markedly increased risk of a similar type of cancer.
Major action/change is likely to be empowerment provided by new knowledge and associated psychological benefit, given that the new knowledge is largely reassuring regarding prognosis. The impact is small at population level, because this is relevant only to Apert syndrome (prevalence ~1 in 65,000); but nevertheless important for this group of individuals.
Benefits reported so far
Not stated in the register.
Datasets on the current version
Legal basis for provision: Health and Social Care Act 2012 – s261(2)(b)(ii)
| Dataset | Type of data | Sensitivity | Frequency | Confidential data |
|---|---|---|---|---|
| MRIS - Cause of Death Report | Identifiable | Sensitive | One-Off | Does not include the flow of confidential data |
| MRIS - Cohort Event Notification Report | Identifiable | Sensitive | One-Off | Does not include the flow of confidential data |
| MRIS - Flagging Current Status Report | Identifiable | Sensitive | One-Off | Does not include the flow of confidential data |
Files released
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
No files recorded as released under this agreement.
Version history
The register lists each renewal of this agreement as a separate row. This site has 3 versions — earlier versions existed before this site's records begin.
DARS-NIC-148106-PP9LS-v4.4 29 September 2025 to 28 September 2026
- Title
- MR461 - A long term follow-up study of Aperts Syndrome
- Commercial
- No
- Sublicensing
- No
- Datasets
- 3
- Files released
- 0
Datasets: MRIS - Cause of Death Report; MRIS - Cohort Event Notification Report; MRIS - Flagging Current Status Report
What changed from DARS-NIC-148106-PP9LS-v3.2
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2025-09-29 | |
| End date | 2026-09-28 |
Objective for processing
Civil Registration mortality data and Cancer Registration data were supplied to the University of Oxford
The Data will be used
for the purpose of
a research project:
a long-term follow-up study of individuals with Apert Syndrome.
This
Data were collected for this
study
is now complete and closed. This study ran
from 1994 to
2013. Data
2013, from which time no further data have been collected. The original data
processing finished in 2015, when information on ages at event (death, cause
[26 words unchanged]
in aggregated form) have been ready for publication since 2015 but this
has been
was
delayed pending clarification of the legal basis for retaining the data.
This Agreement permits the release of the publication, and the processing of the data for the purpose of secure storage and back up to ensure it is possible to verify the conclusions published from this study..
Over the 10 years that have elapsed since the original data processing in 2015, statistical methodologies have improved. On fresh review of the 2015 manuscript, it has become evident that estimates for standardised mortality ratios could now be substantially improved using better statistical methods. The type of results reported would not change, but improved estimates may be of correspondingly greater value – scientifically, clinically, and for patients with Apert syndrome – in improving our understanding of how the condition affects mortality.
This Agreement does not permit any further processing that involves analysis or linkage other than for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement. Following publication of the study findings, it is possible that the findings will be questioned or challenged by third parties through direct contact with the University of Oxford, contact via the publishing journal or an open letter. In such circumstances, the University of Oxford may re-run the previously analyses undertaken to verify that the published results were accurate and may write a response to be issued directly to the challenger or published. The University of Oxford may not use the data to undertake different analyses to those undertaken during the original analysis.
After the additional data processing, the manuscript would be modified to include the improved estimates of confidence limits of the standardised mortality ratios. This Agreement permits the release of the manuscript for publication, and the processing of the data for the purpose of secure storage and back up to ensure it is possible to verify the conclusions published from this study.
This Agreement does not permit any onward sharing of the data. The data controller may process the data for the purpose of audit.
Following publication of the study findings, it is possible that the findings will be questioned or challenged by third parties through direct contact with the University of Oxford, contact via the publishing journal or an open letter. In such circumstances, the University of Oxford may re-run the previous analyses undertaken to verify that the published results are accurate and may write a response to be issued directly to the challenger, and/or published.
If any further data processing is required in addition to the above purposes or if the data needs to be moved to a different location/organisation the applicant must submit an amendment request to NHS Digital and receive formal approval in an amended Data Sharing Agreement before data is accessed.
[2 paragraphs unchanged]
The University of Oxford used these details to obtain data from the
[22 words unchanged]
for National Statistics (ONS) and then the Health and Social Care Information
Centre (now known as NHS Digital).
Centre.
This detail was used to give the University of Oxford two options;
[3 paragraphs unchanged]
It should be noted that this
This
(currently unpublished) study provides very valuable information for people with Apert syndrome
[59 words unchanged]
in making these findings widely known by publication in the medical literature.
Data collected were mortality and cancer data from 1994 until 2013. Initially data were supplied by OPCS/NHSCR on whether each individual was already deceased, and if so, the cause of death. In the case of individuals still alive, tracing of dates and causes of death, or cancers, continued (following necessary approvals after each administrative reorganisation) by ONS/NHSIC/HSCIC until 8 May 2013
Data collected were mortality, demographics and cancer data from 1994 until 2013. Since then, actions have been taken to pseudonymise the Apert Syndrome data. These included converting date of birth to week and month of birth, deleting names, and deleting NHS Numbers. No identifying details are held by the University of Oxford in respect of this study.
Since then, actions have been taken to pseudonymise the Apert Syndrome data. These included converting date of birth to week and month of birth, deleting names, and deleting NHS Numbers. No identifying details are held by the University of Oxford in respect of this study.
The analysis of the data completed in 2015, when information on ages at event (death, cause of death, still living on 8/5/2013), with all identifiers removed, were provided to a University of Oxford statistician who has completed a paper on this Apert syndrome. No external parties have previously been involved in this work.
The data controller is the University of Oxford which is also the only organisation which has processed this data. The analysis of the data completed in 2015, when information on ages at event (death, cause of death, still living on 8/5/2013), with all identifiers removed, were provided to a University of Oxford statistician who has completed a paper on this Apert syndrome. No external parties have been involved in this work. The findings have been ready for publication since 2015, but this has been delayed pending clarification of the legal basis for retaining the data. Following advice from NHS Digital, the University of Oxford has pseudonymised the data.
Processing activities
This
Data collection for this
study is now
completed and closed.
completed.
This Agreement permits processing of the data for the purpose of secure storage and back up, and for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement.
Additional processing of the data is proposed because estimates for standardised mortality ratios could now be substantially improved using better statistical methods, compared to those available in 2015. Specifically, the previous analysis did not make use of detailed information on population-level mortality rates by calendar year. There have been large changes in mortality rates during the time since the 1959 study on which the data is based. We have assessed that failing to account for these changes could add substantial additional error to the estimates. In this amendment, we therefore propose to use annual, age-specific mortality rates, available from public sources, to calculate more accurate estimates of standardised mortality rates for this cohort of patients with Apert syndrome.
All data analysis by the statistical epidemiologist would take place physically based in the office of the Principal Investigator, located at MRC-Weatherall Institute of Molecular Medicine, University of Oxford (MRC-WIMM). The data are housed on an encrypted memory stick which would be accessed using a laptop computer in the MRC-WIMM. A backup data file will be kept on a second encrypted memory stick with identical security specifications. The statistical epidemiologist would access summary mortality datasets online and use these to estimate mortality rates for the general population at the same ages and chronological times as observed for the individuals with Apert syndrome in this study. These mortality rates will be used to compute the total expected number of deaths for the individuals in the study if they had no difference in mortality from the general population. Standardised mortality rates will then be computed by dividing the observed number of deaths in the study by the expected number.
[3 paragraphs unchanged]
The
data
Data
may not be transferred to any other location and may only be accessed by substantive employees of the University of Oxford
or named Honorary Contract holders
for the purposes described above.
The data originally requested from NHS Digital was for use in the long-term follow-up study of Apert Syndrome. Civil registration mortality and Cancer Registrations data were used to follow-up individuals involved in the study.
Study data needs to be retained and accessible for 2 years after publication.
Study data needs to be retained and accessible for 5 years after publication.
Expected output
This study is now completed and closed.
Further processing of the data will be undertaken by the statistical epidemiologist as described in the previous section, to enable improved estimates of standardised mortality rates for this cohort of patients with Apert syndrome. These estimates will be incorporated into the revised manuscript prepared in 2015, which will be submitted for publication. No other analyses will be undertaken using the data under this Agreement.
On approval of this Data Sharing Agreement, a completed publication from 2015 will become publicly available. No new analyses will be undertaken using the data under this Agreement.
[1 paragraph unchanged]
A summary of the findings would be published in a peer-reviewed medical genetics journal, for example, American
Journal of Medical Genetics.
Causes of death, or whether still alive at the end of the study, would be summarised in 5-year bins. As there are only 24 data subjects in the study, each 5-year bins contain fewer than 5 individuals and consequently if someone knew of a person who had Apert syndrome and was in the 1959 study and died within a specific 5-year age-range, they may be able to identify that person. However, the only additional information they may be able to determine about this individual from the summary data might be their primary cause of death which is a matter of public record. Death and cancer data would be summarised in the form of Kaplan-Meier survival curves or similar demonstrating the proportion of individuals still alive at a given age.
Journal of Medical Genetics.
Causes of death, or whether still alive at the end of the study, would be summarised in 5-year bins. As there are only 24 data subjects in the study, each 5-year bin contains fewer than 5 individuals and consequently if someone knew of a person who had Apert syndrome and was in the 1959 study and died within a specific 5-year age-range, they may be able to identify that person. However, the only additional information they may be able to determine about this individual from the summary data might be their primary cause of death which is a matter of public record. Death and cancer data would be summarised in the form of Kaplan-Meier survival curves or similar demonstrating the proportion of individuals still alive at a given age.
[2 paragraphs unchanged]
The Publication is expected to be made available for submission of manuscript for peer-review towards the end of
2019, with publication and associated Headlines article in 2020.
2025, with publication and associated Headlines article in 2026.
[1 paragraph unchanged]
Expected measurable benefits
This data will be retained to comply with guidance and policy on good clinical practice and regulations. It also preserves a unique database which could still yield future benefits for young families by looking at the effects on children in the longer term.
[4 paragraphs unchanged]
(ii) Scientific. It is known that one of the most common genetic
[8 words unchanged]
mutation to that causing Apert syndrome, but occurring as a somatic mutation
(ie,
(i.e.
in a particular cell in the body at a later stage of
[23 words unchanged]
necessarily associated with markedly increased risk of a similar type of cancer.
[1 paragraph unchanged]
This agreement seeks to assure data integrity for a reasonable period of time (up to 5 years) following dissemination. This will enable evidence supporting findings to be examined, if necessary, should be findings be questioned or challenged for reputable scientific reasons.
Benefits reported
Stated in the previous version and removed here.
None, as the work has remained unpublished up to this point.
DARS-NIC-148106-PP9LS-v3.2 2 August 2024 to 1 August 2025
- Title
- MR461 - A long term follow-up study of Aperts Syndrome
- Commercial
- No
- Sublicensing
- No
- Datasets
- 3
- Files released
- 0
Datasets: MRIS - Cause of Death Report; MRIS - Cohort Event Notification Report; MRIS - Flagging Current Status Report
What changed from DARS-NIC-148106-PP9LS-v2.4
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2024-08-02 | |
| End date | 2025-08-01 | |
| MRIS - Cause of Death Report: type of data | Identifiable | |
| MRIS - Cohort Event Notification Report: type of data | Identifiable | |
| MRIS - Flagging Current Status Report: type of data | Identifiable |
Processing activities
[1 paragraph unchanged]
This Agreement permits processing of the data for the purpose of secure storage and back
up.
up, and for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement.
This Agreement does not permit any further processing that involves analysis or linkage other than for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement.
[6 paragraphs unchanged]
Unchanged: Objective for processing, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
Civil Registration mortality data and Cancer Registration data were supplied to the University of Oxford for the purpose of a long-term follow-up study of individuals with Apert Syndrome.
This study is now complete and closed. This study ran from 1994 to 2013. Data processing finished in 2015, when information on ages at event (death, cause of death, still living on 08/05/2013), with all identifiers removed, were provided to a statistical epidemiologist substantively employed by the University of Oxford. The findings (now in aggregated form) have been ready for publication since 2015 but this has been delayed pending clarification of the legal basis for retaining the data.
This Agreement permits the release of the publication, and the processing of the data for the purpose of secure storage and back up to ensure it is possible to verify the conclusions published from this study..
This Agreement does not permit any further processing that involves analysis or linkage other than for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement. Following publication of the study findings, it is possible that the findings will be questioned or challenged by third parties through direct contact with the University of Oxford, contact via the publishing journal or an open letter. In such circumstances, the University of Oxford may re-run the previously analyses undertaken to verify that the published results were accurate and may write a response to be issued directly to the challenger or published. The University of Oxford may not use the data to undertake different analyses to those undertaken during the original analysis.
This Agreement does not permit any onward sharing of the data. The data controller may process the data for the purpose of audit.
If any further data processing is required in addition to the above purposes or if the data needs to be moved to a different location/organisation the applicant must submit an amendment request to NHS Digital and receive formal approval in an amended Data Sharing Agreement before data is accessed.
Since 1960 there has been very little further research into Apert syndrome in this country until in 1994 a new study was created at the University of Oxford. The purpose of this new study at the University of Oxford was to try to find out what causes Apert syndrome. Apert syndrome is a rare malformation syndrome comprising two distinctive features, namely a characteristic appearance of the face and skull due to early closure of the skull bones (craniosynostosis) and bony fusions of the fingers and toes (syndactyly). This due to an alteration in one of the many thousands of genetic instructions which human beings carry from the time of conception. This study has already managed to identify which particular genetic instruction is altered, but much work needs to be done to try to understand why the alteration occurs in the first place, and how it causes the features of Apert syndrome.
In 1994 the University of Oxford sought permission from the head researcher of the 1959 study (who was based at the University of Sheffield) in order to obtain the names and dates of birth of the 24 participants in the 1959 study. These are the only data subjects.
The University of Oxford used these details to obtain data from the Medical Research service under the Office of Population Censuses and Surveys (OPCS). in January 1995. The service subsequently transferred to the Office for National Statistics (ONS) and then the Health and Social Care Information Centre (now known as NHS Digital). This detail was used to give the University of Oxford two options;
1 - Should the participant have passed away at time of flagging, the University of Oxford obtained the cause of death, and cancer registration data to understand whether there was an increased incidence of certain cancers.
2 - Should the participant be alive at time of flagging, the University of Oxford would invite them through their General Practitioner to take part in the study.
This study is considered to be in the public interest because it provides new (not previously available) information on the long-term survival of the medical disorder Apert syndrome. The retention of the data, which is now pseudonymised, is not expected to raise ethical issues because no individually identifying information on ages and causes of death is held.
It should be noted that this (currently unpublished) study provides very valuable information for people with Apert syndrome and their parents and carers, because it establishes for the first time that many individuals with the condition live into their 50s-70s. Moreover, although mortality is higher than average before this age, the causes are varied with no one frequent cause (for example a particular type of cancer), being revealed by the data. There is a strong public interest in making these findings widely known by publication in the medical literature.
Data collected were mortality and cancer data from 1994 until 2013. Initially data were supplied by OPCS/NHSCR on whether each individual was already deceased, and if so, the cause of death. In the case of individuals still alive, tracing of dates and causes of death, or cancers, continued (following necessary approvals after each administrative reorganisation) by ONS/NHSIC/HSCIC until 8 May 2013
Since then, actions have been taken to pseudonymise the Apert Syndrome data. These included converting date of birth to week and month of birth, deleting names, and deleting NHS Numbers. No identifying details are held by the University of Oxford in respect of this study.
The data controller is the University of Oxford which is also the only organisation which has processed this data. The analysis of the data completed in 2015, when information on ages at event (death, cause of death, still living on 8/5/2013), with all identifiers removed, were provided to a University of Oxford statistician who has completed a paper on this Apert syndrome. No external parties have been involved in this work. The findings have been ready for publication since 2015, but this has been delayed pending clarification of the legal basis for retaining the data. Following advice from NHS Digital, the University of Oxford has pseudonymised the data.
Expected output
This study is now completed and closed.
On approval of this Data Sharing Agreement, a completed publication from 2015 will become publicly available. No new analyses will be undertaken using the data under this Agreement.
An online article would be prepared for Headlines, the UK Craniofacial Support Group, so that parents of children with Apert syndrome, and affected young adults, would be made aware of the findings. No new use of the data would be required for this. It would simply be targeting the already-existing information to a specific audience and in simple language.
A summary of the findings would be published in a peer-reviewed medical genetics journal, for example, American Journal of Medical Genetics.
Causes of death, or whether still alive at the end of the study, would be summarised in 5-year bins. As there are only 24 data subjects in the study, each 5-year bins contain fewer than 5 individuals and consequently if someone knew of a person who had Apert syndrome and was in the 1959 study and died within a specific 5-year age-range, they may be able to identify that person. However, the only additional information they may be able to determine about this individual from the summary data might be their primary cause of death which is a matter of public record. Death and cancer data would be summarised in the form of Kaplan-Meier survival curves or similar demonstrating the proportion of individuals still alive at a given age.
An Open Access charge would be paid to the publisher of the peer-reviewed article, to ensure that the article could be read by anybody wishing to do so.
The Headlines web-based article would ensure that the knowledge reached the relevant patient/parent group.
The Publication is expected to be made available for submission of manuscript for peer-review towards the end of 2019, with publication and associated Headlines article in 2020.
This is the sole planned data dissemination and therefore integral to the overall purpose of the work.
Benefits reported
None, as the work has remained unpublished up to this point.
DARS-NIC-148106-PP9LS-v2.4 1 August 2019 to 31 July 2024
- Title
- MR461 - A long term follow-up study of Aperts Syndrome
- Commercial
- No
- Sublicensing
- No
- Datasets
- 3
- Files released
- 0
Datasets: MRIS - Cause of Death Report; MRIS - Cohort Event Notification Report; MRIS - Flagging Current Status Report
Objective for processing
Civil Registration mortality data and Cancer Registration data were supplied to the University of Oxford for the purpose of a long-term follow-up study of individuals with Apert Syndrome.
This study is now complete and closed. This study ran from 1994 to 2013. Data processing finished in 2015, when information on ages at event (death, cause of death, still living on 08/05/2013), with all identifiers removed, were provided to a statistical epidemiologist substantively employed by the University of Oxford. The findings (now in aggregated form) have been ready for publication since 2015 but this has been delayed pending clarification of the legal basis for retaining the data.
This Agreement permits the release of the publication, and the processing of the data for the purpose of secure storage and back up to ensure it is possible to verify the conclusions published from this study..
This Agreement does not permit any further processing that involves analysis or linkage other than for the purpose of verifying findings in line with the original objectives of the study by repeating previous analyses described in this Agreement. Following publication of the study findings, it is possible that the findings will be questioned or challenged by third parties through direct contact with the University of Oxford, contact via the publishing journal or an open letter. In such circumstances, the University of Oxford may re-run the previously analyses undertaken to verify that the published results were accurate and may write a response to be issued directly to the challenger or published. The University of Oxford may not use the data to undertake different analyses to those undertaken during the original analysis.
This Agreement does not permit any onward sharing of the data. The data controller may process the data for the purpose of audit.
If any further data processing is required in addition to the above purposes or if the data needs to be moved to a different location/organisation the applicant must submit an amendment request to NHS Digital and receive formal approval in an amended Data Sharing Agreement before data is accessed.
Since 1960 there has been very little further research into Apert syndrome in this country until in 1994 a new study was created at the University of Oxford. The purpose of this new study at the University of Oxford was to try to find out what causes Apert syndrome. Apert syndrome is a rare malformation syndrome comprising two distinctive features, namely a characteristic appearance of the face and skull due to early closure of the skull bones (craniosynostosis) and bony fusions of the fingers and toes (syndactyly). This due to an alteration in one of the many thousands of genetic instructions which human beings carry from the time of conception. This study has already managed to identify which particular genetic instruction is altered, but much work needs to be done to try to understand why the alteration occurs in the first place, and how it causes the features of Apert syndrome.
In 1994 the University of Oxford sought permission from the head researcher of the 1959 study (who was based at the University of Sheffield) in order to obtain the names and dates of birth of the 24 participants in the 1959 study. These are the only data subjects.
The University of Oxford used these details to obtain data from the Medical Research service under the Office of Population Censuses and Surveys (OPCS). in January 1995. The service subsequently transferred to the Office for National Statistics (ONS) and then the Health and Social Care Information Centre (now known as NHS Digital). This detail was used to give the University of Oxford two options;
1 - Should the participant have passed away at time of flagging, the University of Oxford obtained the cause of death, and cancer registration data to understand whether there was an increased incidence of certain cancers.
2 - Should the participant be alive at time of flagging, the University of Oxford would invite them through their General Practitioner to take part in the study.
This study is considered to be in the public interest because it provides new (not previously available) information on the long-term survival of the medical disorder Apert syndrome. The retention of the data, which is now pseudonymised, is not expected to raise ethical issues because no individually identifying information on ages and causes of death is held.
It should be noted that this (currently unpublished) study provides very valuable information for people with Apert syndrome and their parents and carers, because it establishes for the first time that many individuals with the condition live into their 50s-70s. Moreover, although mortality is higher than average before this age, the causes are varied with no one frequent cause (for example a particular type of cancer), being revealed by the data. There is a strong public interest in making these findings widely known by publication in the medical literature.
Data collected were mortality and cancer data from 1994 until 2013. Initially data were supplied by OPCS/NHSCR on whether each individual was already deceased, and if so, the cause of death. In the case of individuals still alive, tracing of dates and causes of death, or cancers, continued (following necessary approvals after each administrative reorganisation) by ONS/NHSIC/HSCIC until 8 May 2013
Since then, actions have been taken to pseudonymise the Apert Syndrome data. These included converting date of birth to week and month of birth, deleting names, and deleting NHS Numbers. No identifying details are held by the University of Oxford in respect of this study.
The data controller is the University of Oxford which is also the only organisation which has processed this data. The analysis of the data completed in 2015, when information on ages at event (death, cause of death, still living on 8/5/2013), with all identifiers removed, were provided to a University of Oxford statistician who has completed a paper on this Apert syndrome. No external parties have been involved in this work. The findings have been ready for publication since 2015, but this has been delayed pending clarification of the legal basis for retaining the data. Following advice from NHS Digital, the University of Oxford has pseudonymised the data.
Expected output
This study is now completed and closed.
On approval of this Data Sharing Agreement, a completed publication from 2015 will become publicly available. No new analyses will be undertaken using the data under this Agreement.
An online article would be prepared for Headlines, the UK Craniofacial Support Group, so that parents of children with Apert syndrome, and affected young adults, would be made aware of the findings. No new use of the data would be required for this. It would simply be targeting the already-existing information to a specific audience and in simple language.
A summary of the findings would be published in a peer-reviewed medical genetics journal, for example, American Journal of Medical Genetics.
Causes of death, or whether still alive at the end of the study, would be summarised in 5-year bins. As there are only 24 data subjects in the study, each 5-year bins contain fewer than 5 individuals and consequently if someone knew of a person who had Apert syndrome and was in the 1959 study and died within a specific 5-year age-range, they may be able to identify that person. However, the only additional information they may be able to determine about this individual from the summary data might be their primary cause of death which is a matter of public record. Death and cancer data would be summarised in the form of Kaplan-Meier survival curves or similar demonstrating the proportion of individuals still alive at a given age.
An Open Access charge would be paid to the publisher of the peer-reviewed article, to ensure that the article could be read by anybody wishing to do so.
The Headlines web-based article would ensure that the knowledge reached the relevant patient/parent group.
The Publication is expected to be made available for submission of manuscript for peer-review towards the end of 2019, with publication and associated Headlines article in 2020.
This is the sole planned data dissemination and therefore integral to the overall purpose of the work.
Benefits reported
None, as the work has remained unpublished up to this point.
Register history
When this agreement appeared in, or was edited in, each monthly edition of the register. Built by comparing every edition this site holds, the earliest of which is July 2021.
-
July 2021 —
already listed in the earliest edition this site holds, so it may be older. 1 version: DARS-NIC-148106-PP9LS-v2.4
-
December 2022
Register-wide edit DARS-NIC-148106-PP9LS-v2.4 — Datasets: legal basis: “
s261(1) and” taken out. Made to 639 agreements in this edition, so it is reported once, on the changes page, and not counted as an amendment of this agreement. -
October 2024
1 version added: DARS-NIC-148106-PP9LS-v3.2
-
November 2025
1 version added: DARS-NIC-148106-PP9LS-v4.4
Cite this page
NHS England (2026) Data Uses Register, September 2026 edition, agreement DARS-NIC-148106-PP9LS, “MR461 - A long term follow-up study of Aperts Syndrome”. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/agreements/dars-nic-148106-pp9ls/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.
Source: datausesregister_september2026.xlsx, September 2026 edition of the NHS England Data Uses Register. Search that workbook for DARS-NIC-148106-PP9LS to see the original rows.